<code id='2BEA36BD02'></code><style id='2BEA36BD02'></style>
    • <acronym id='2BEA36BD02'></acronym>
      <center id='2BEA36BD02'><center id='2BEA36BD02'><tfoot id='2BEA36BD02'></tfoot></center><abbr id='2BEA36BD02'><dir id='2BEA36BD02'><tfoot id='2BEA36BD02'></tfoot><noframes id='2BEA36BD02'>

    • <optgroup id='2BEA36BD02'><strike id='2BEA36BD02'><sup id='2BEA36BD02'></sup></strike><code id='2BEA36BD02'></code></optgroup>
        1. <b id='2BEA36BD02'><label id='2BEA36BD02'><select id='2BEA36BD02'><dt id='2BEA36BD02'><span id='2BEA36BD02'></span></dt></select></label></b><u id='2BEA36BD02'></u>
          <i id='2BEA36BD02'><strike id='2BEA36BD02'><tt id='2BEA36BD02'><pre id='2BEA36BD02'></pre></tt></strike></i>

          Home / explore / entertainment

          entertainment


          entertainment

          author:Wikipedia    Page View:57
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In